JO3587B1 - أشكال جرعات بينداموستين عن طريق الفم - Google Patents

أشكال جرعات بينداموستين عن طريق الفم

Info

Publication number
JO3587B1
JO3587B1 JOP/2011/0180A JOP20110180A JO3587B1 JO 3587 B1 JO3587 B1 JO 3587B1 JO P20110180 A JOP20110180 A JO P20110180A JO 3587 B1 JO3587 B1 JO 3587B1
Authority
JO
Jordan
Prior art keywords
bendamustine
dosage forms
oral dosage
pharmaceutically acceptable
solvate
Prior art date
Application number
JOP/2011/0180A
Other languages
English (en)
Inventor
Margaretha Olthoff
Jeffrey Colledge
Original Assignee
Astellas Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44243599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3587(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Deutschland Gmbh filed Critical Astellas Deutschland Gmbh
Application granted granted Critical
Publication of JO3587B1 publication Critical patent/JO3587B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة صيدلانية تؤخذ عن طريق الفم، وتشتمل على بنداميوستين أو إستر أو ملح أو ذوابة منه مقبولين صيدلانيًا كمكون فعال، وسواغ مقبول صيدلانيًا، يكون عبارة عن مادة خافضة للتوتر السطحي آلفة للماء وغير أيونية مقبولة صيدلانيًا.
JOP/2011/0180A 2010-06-02 2011-06-01 أشكال جرعات بينداموستين عن طريق الفم JO3587B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10075231 2010-06-02
EP11075047 2011-03-14

Publications (1)

Publication Number Publication Date
JO3587B1 true JO3587B1 (ar) 2020-07-05

Family

ID=44243599

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0180A JO3587B1 (ar) 2010-06-02 2011-06-01 أشكال جرعات بينداموستين عن طريق الفم

Country Status (26)

Country Link
US (2) US20130202693A1 (ar)
EP (1) EP2575784B1 (ar)
JP (2) JP6209446B2 (ar)
KR (1) KR101830142B1 (ar)
CN (1) CN103037851A (ar)
AR (1) AR081835A1 (ar)
AU (1) AU2011260615B2 (ar)
BR (1) BR112012030654B1 (ar)
CA (1) CA2800279A1 (ar)
CL (1) CL2012003341A1 (ar)
CO (1) CO6640318A2 (ar)
DK (1) DK2575784T3 (ar)
EA (1) EA031793B1 (ar)
ES (1) ES2690257T3 (ar)
IL (1) IL223311B (ar)
JO (1) JO3587B1 (ar)
MX (1) MX2012013872A (ar)
MY (1) MY173873A (ar)
NZ (1) NZ603872A (ar)
PH (1) PH12012502281B1 (ar)
PL (1) PL2575784T3 (ar)
PT (1) PT2575784T (ar)
SG (1) SG186099A1 (ar)
TW (1) TWI500431B (ar)
WO (1) WO2011151087A1 (ar)
ZA (1) ZA201208823B (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2864118A1 (en) * 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
SI2849723T1 (sl) * 2012-05-18 2018-09-28 Genentech, Inc. Formulacije z visoko koncentracijo monoklonskih protiteles
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
EP2917183A1 (en) 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (ar) * 1903-10-08 1905-03-16
US20030044434A1 (en) * 1997-07-29 2003-03-06 Ping Gao Self-emulsifying formulation for lipophilic compounds
FR2781373B1 (fr) * 1998-07-07 2001-09-21 Pf Medicament Formulations thixotropes pour le remplissage de gelules
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AU2002255190A1 (en) 2001-04-10 2002-10-28 Fakhreddin Jamali Composition for enhanced absorption of nsaids
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
JP2006518380A (ja) 2003-01-31 2006-08-10 スミスクライン・ビーチャム・コーポレイション 固体分散体組成物
WO2004071490A1 (en) 2003-02-12 2004-08-26 R & P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1814544A4 (en) * 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
CN101052396A (zh) * 2004-11-05 2007-10-10 赛福伦公司 癌症治疗
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
GB0526419D0 (en) 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
MX2009000145A (es) * 2006-06-30 2009-01-23 Mcneil Ppc Inc Capsulas duras llenas con liquido que contiene ibuprofeno.
EP2144601A4 (en) * 2007-04-05 2012-10-10 Univ Kansas RAPID DISSOLVING PHARMACEUTICAL COMPOSITIONS COMPRISING PULLULANE
JP2010533205A (ja) * 2007-07-12 2010-10-21 トラガラ ファーマシューティカルズ，インク． 癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
KR100913644B1 (ko) 2007-10-09 2009-08-24 제일약품주식회사 활성성분으로 시부트라민 유리염기를 함유하는 약제학적조성물 및 그 제조방법
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
PL2299987T3 (pl) * 2008-06-06 2018-08-31 Boehringer Ingelheim International Gmbh Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
NZ592970A (en) * 2008-12-03 2013-05-31 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
JP2012525387A (ja) * 2009-04-28 2012-10-22 セファロン、インク． ベンダムスチンの経口製剤
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter

Also Published As

Publication number Publication date
MY173873A (en) 2020-02-25
CL2012003341A1 (es) 2013-06-28
EA031793B1 (ru) 2019-02-28
JP6373300B2 (ja) 2018-08-15
SG186099A1 (en) 2013-01-30
PH12012502281B1 (en) 2017-10-20
PT2575784T (pt) 2018-10-26
CA2800279A1 (en) 2011-12-08
AU2011260615B2 (en) 2016-11-17
PL2575784T3 (pl) 2019-03-29
US10993933B2 (en) 2021-05-04
US20130202693A1 (en) 2013-08-08
DK2575784T3 (en) 2018-10-15
EP2575784B1 (en) 2018-08-08
IL223311A0 (en) 2013-02-03
CO6640318A2 (es) 2013-03-22
EA201291104A1 (ru) 2013-06-28
US20150374670A1 (en) 2015-12-31
EP2575784A1 (en) 2013-04-10
AR081835A1 (es) 2012-10-24
ZA201208823B (en) 2014-01-29
BR112012030654B1 (pt) 2021-11-09
KR101830142B1 (ko) 2018-02-20
JP2016153438A (ja) 2016-08-25
MX2012013872A (es) 2013-04-03
TWI500431B (zh) 2015-09-21
PH12012502281A1 (en) 2013-02-11
WO2011151087A1 (en) 2011-12-08
ES2690257T3 (es) 2018-11-20
JP2013527207A (ja) 2013-06-27
TW201210635A (en) 2012-03-16
IL223311B (en) 2018-04-30
AU2011260615A1 (en) 2013-01-10
JP6209446B2 (ja) 2017-10-04
NZ603872A (en) 2014-07-25
CN103037851A (zh) 2013-04-10
KR20130086157A (ko) 2013-07-31
BR112012030654A2 (pt) 2016-08-16

Similar Documents

Publication Publication Date Title
MX2011005643A (es) Formas de dosificacion oral de bendamustina.
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
MX369121B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MY177741A (en) Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate.
MY173873A (en) Oral dosage forms of bendamustine
CY1118032T1 (el) Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
WO2011101863A3 (en) Extended release pharmaceutical compositions of lacosamide
MX343689B (es) Formulaciones combinadas de darunavir.
WO2011019326A3 (en) Solubility and stability enchancing pharmaceutical formulation
MX341976B (es) Formulaciones de darunavir.
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
WO2012064302A3 (en) Improved montelukast formulations
MX346316B (es) Formulacion farmaceutica o nutraceutica.
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
TR201803451T4 (tr) Olmesartan formülasyonlari.
MX2012007393A (es) Composicion farmaceutica de disolucion rapida comprendiendo lornoxicam.
EP3010534A4 (en) Pharmaceutical formulations and methods for oral delivery of biologically active ingredient
EP2409685A3 (en) Orally-disintegrating formulations of prasugrel
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
UA110792C2 (uk) Лікарська форма бендамустину для перорального застосування
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate
UA97044C2 (ru) Средство противовирусной и иммуностимулирующей активности, способ получения средства противовирусной и иммуностимулирующей активности, способ профилактики и лечения инфекционных болезней
UA105513C2 (uk) Лікарська форма уповільненого вивільнення глюкозаміну